Search

Your search keyword '"Tehozol, Erick Adrian Zamora"' showing total 8 results
Start Over Author "Tehozol, Erick Adrian Zamora"

Refine your results

more »

more »
8 results on '"Tehozol, Erick Adrian Zamora"'

1. Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study

Author

Sandhu, Nimrat Kaur, Ravichandraan, Naveen, Nune, Arvind, Day, Jessica, Sen, Parikshit, Nikiphorou, Elena, Tan, Ai Lyn, Joshi, Mrudula, Saha, Sreoshy, Shinjo, Samuel Katsuyuki, Jagtap, Kshitij, Agarwal, Vishwesh, Ziade, Nelly, Velikova, Tsvetelina, Milchert, Marcin, Parodis, Ioannis, Gracia‐Ramos, Abraham Edgar, Cavagna, Lorenzo, Kuwana, Masataka, Knitza, Johannes, Makol, Ashima, Patel, Aarat, Pauling, John D, Wincup, Chris, Barman, Bhupen, Tehozol, Erick Adrian Zamora, Serrano, Jorge Rojas, La Torre, Ignacio García‐De, Colunga‐Pedraza, Iris J, Merayo‐Chalico, Javier, Okwara, Celestine Chibuzo, Katchamart, Wanruchada, Goo, Phonpen Akawatcharangura, Shumnalieva, Russka, Chen, Yi‐Ming, Hoff, Leonardo Santos, Kibbi, Lina El, Halabi, Hussein, Vaidya, Binit, Shaharir, Syahrul Sazliyana, Hasan, ATM Tanveer, Dey, Dzifa, Gutiérrez, Carlos Enrique Toro, Caballero‐Uribe, Carlo Vinicio, Lilleker, James B, Salim, Babur, Gheita, Tamer, Saavedra, Miguel A, Chatterjee, Tulika, Distler, Oliver, Group, COVAD Study, Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, and Gupta, Latika

Subjects
Biomedical and Clinical Sciences, Immunology, Autoimmune Disease, Emerging Infectious Diseases, Infectious Diseases, Arthritis, Coronaviruses, Humans, COVID-19, Rheumatic Diseases, Autoimmune Diseases, COVAD Study Group, Arthritis & Rheumatology
Published
2024

2. Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

Author

Doskaliuk, Bohdana, Ravichandran, Naveen, Sen, Parikshit, Day, Jessica, Joshi, Mrudula, Nune, Arvind, Nikiphorou, Elena, Saha, Sreoshy, Tan, Ai Lyn, Shinjo, Samuel Katsuyuki, Ziade, Nelly, Velikova, Tsvetelina, Milchert, Marcin, Jagtap, Kshitij, Parodis, Ioannis, Gracia-Ramos, Abraham Edgar, Cavagna, Lorenzo, Kuwana, Masataka, Knitza, Johannes, Chen, Yi Ming, Makol, Ashima, Agarwal, Vishwesh, Patel, Aarat, Pauling, John D., Wincup, Chris, Barman, Bhupen, Tehozol, Erick Adrian Zamora, Serrano, Jorge Rojas, La Torre, Ignacio García-De, Colunga-Pedraza, Iris J., Merayo-Chalico, Javier, Chibuzo, Okwara Celestine, Katchamart, Wanruchada, Goo, Phonpen Akarawatcharangura, Shumnalieva, Russka, Hoff, Leonardo Santos, Kibbi, Lina El, Halabi, Hussein, Vaidya, Binit, Shaharir, Syahrul Sazliyana, Hasan, A. T. M. Tanveer, Dey, Dzifa, Gutiérrez, Carlos Enrique Toro, Caballero-Uribe, Carlo V., Lilleker, James B., Salim, Babur, Gheita, Tamer, Chatterjee, Tulika, Distler, Oliver, Saavedra, Miguel A., Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, and Gupta, Latika

Published
2023
Full Text
View/download PDF

3. COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey

Author

Hoff, Leonardo Santos, Ravichandran, Naveen, Shinjo, Samuel Katsuyuki, Day, Jessica, Sen, Parikshit, Junior, Jucier Gonçalves, Lilleker, James B., Joshi, Mrudula, Agarwal, Vishwesh, Kardes, Sinan, Kim, Minchul, Milchert, Marcin, Makol, Ashima, Gheita, Tamer, Salim, Babur, Velikova, Tsvetelina, Gracia-Ramos, Abraham Edgar, Parodis, Ioannis, O’Callaghan, Albert Selva, Nikiphorou, Elena, Tan, Ai Lyn, Chatterjee, Tulika, Cavagna, Lorenzo, Saavedra, Miguel A., Ziade, Nelly, Knitza, Johannes, Kuwana, Masataka, Nune, Arvind, Distler, Oliver, Cansu, Döndü Üsküdar, Traboco, Lisa, Wibowo, Suryo Angorro Kusumo, Tehozol, Erick Adrian Zamora, Serrano, Jorge Rojas, La Torre, Ignacio García-De, Wincup, Chris, Pauling, John D., Chinoy, Hector, Agarwal, Vikas, Aggarwal, Rohit, and Gupta, Latika

Published
2023
Full Text
View/download PDF

4. Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study

Author

Doskaliuk, Bohdana; https://orcid.org/0000-0003-1650-8928, Ravichandran, Naveen; https://orcid.org/0000-0003-2014-3925, Sen, Parikshit; https://orcid.org/0000-0002-1630-6026, Day, Jessica; https://orcid.org/0000-0001-8528-4361, Joshi, Mrudula; https://orcid.org/0000-0001-7312-351X, Nune, Arvind; https://orcid.org/0000-0002-3849-614X, Nikiphorou, Elena; https://orcid.org/0000-0001-6847-3726, Saha, Sreoshy; https://orcid.org/0000-0001-6745-9770, Tan, Ai Lyn; https://orcid.org/0000-0002-9158-7243, Shinjo, Samuel Katsuyuki; https://orcid.org/0000-0002-3682-4517, Ziade, Nelly; https://orcid.org/0000-0002-4479-7678, Velikova, Tsvetelina; https://orcid.org/0000-0002-0593-1272, Milchert, Marcin; https://orcid.org/0000-0002-0943-8768, Jagtap, Kshitij; https://orcid.org/0000-0003-2729-737X, Parodis, Ioannis; https://orcid.org/0000-0002-4875-5395, Gracia-Ramos, Abraham Edgar; https://orcid.org/0000-0003-1842-2554, Cavagna, Lorenzo; https://orcid.org/0000-0003-3292-1528, Kuwana, Masataka; https://orcid.org/0000-0001-8352-6136, Knitza, Johannes; https://orcid.org/0000-0001-9695-0657, Chen, Yi Ming; https://orcid.org/0000-0001-7593-3065, Makol, Ashima; https://orcid.org/0000-0002-8748-898X, Agarwal, Vishwesh; https://orcid.org/0000-0002-0986-8354, Patel, Aarat, Pauling, John D; https://orcid.org/0000-0002-2793-2364, Wincup, Chris; https://orcid.org/0000-0002-8742-8311, Barman, Bhupen; https://orcid.org/0000-0002-5433-1310, Tehozol, Erick Adrian Zamora; https://orcid.org/0000-0002-7888-3961, Serrano, Jorge Rojas; https://orcid.org/0000-0001-6980-7898, La Torre, Ignacio García-De; https://orcid.org/0000-0002-9261-678X, Colunga-Pedraza, Iris J; https://orcid.org/0000-0002-2786-5843, et al, Distler, Oliver; https://orcid.org/0000-0002-0546-8310, Doskaliuk, Bohdana; https://orcid.org/0000-0003-1650-8928, Ravichandran, Naveen; https://orcid.org/0000-0003-2014-3925, Sen, Parikshit; https://orcid.org/0000-0002-1630-6026, Day, Jessica; https://orcid.org/0000-0001-8528-4361, Joshi, Mrudula; https://orcid.org/0000-0001-7312-351X, Nune, Arvind; https://orcid.org/0000-0002-3849-614X, Nikiphorou, Elena; https://orcid.org/0000-0001-6847-3726, Saha, Sreoshy; https://orcid.org/0000-0001-6745-9770, Tan, Ai Lyn; https://orcid.org/0000-0002-9158-7243, Shinjo, Samuel Katsuyuki; https://orcid.org/0000-0002-3682-4517, Ziade, Nelly; https://orcid.org/0000-0002-4479-7678, Velikova, Tsvetelina; https://orcid.org/0000-0002-0593-1272, Milchert, Marcin; https://orcid.org/0000-0002-0943-8768, Jagtap, Kshitij; https://orcid.org/0000-0003-2729-737X, Parodis, Ioannis; https://orcid.org/0000-0002-4875-5395, Gracia-Ramos, Abraham Edgar; https://orcid.org/0000-0003-1842-2554, Cavagna, Lorenzo; https://orcid.org/0000-0003-3292-1528, Kuwana, Masataka; https://orcid.org/0000-0001-8352-6136, Knitza, Johannes; https://orcid.org/0000-0001-9695-0657, Chen, Yi Ming; https://orcid.org/0000-0001-7593-3065, Makol, Ashima; https://orcid.org/0000-0002-8748-898X, Agarwal, Vishwesh; https://orcid.org/0000-0002-0986-8354, Patel, Aarat, Pauling, John D; https://orcid.org/0000-0002-2793-2364, Wincup, Chris; https://orcid.org/0000-0002-8742-8311, Barman, Bhupen; https://orcid.org/0000-0002-5433-1310, Tehozol, Erick Adrian Zamora; https://orcid.org/0000-0002-7888-3961, Serrano, Jorge Rojas; https://orcid.org/0000-0001-6980-7898, La Torre, Ignacio García-De; https://orcid.org/0000-0002-9261-678X, Colunga-Pedraza, Iris J; https://orcid.org/0000-0002-2786-5843, et al, and Distler, Oliver; https://orcid.org/0000-0002-0546-8310

Abstract

Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.

Published
2023

5. Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study.

Author

Naveen, R, Nikiphorou, Elena, Joshi, Mrudula, Sen, Parikshit, Lindblom, Julius, Agarwal, Vishwesh, Lilleker, James B, Tan, Ai Lyn, Salim, Babur, Ziade, Nelly, Velikova, Tsvetelina, Gracia-Ramos, Abraham Edgar, Kuwana, Masataka, Day, Jessica, Makol, Ashima, Distler, Oliver, Chinoy, Hector, Traboco, Lisa S, Wibowo, Suryo Anggoro Kusumo, and Tehozol, Erick Adrian Zamora

Subjects
VACCINES, DRUG tolerance, COVID-19, CONFIDENCE intervals, FEVER, MULTIVARIATE analysis, AUTOIMMUNE diseases, REGRESSION analysis, SHIVERING, QUESTIONNAIRES, HOSPITAL care, SYSTEMIC lupus erythematosus, ODDS ratio, ADVERSE health care events, PATIENT safety, DISEASE risk factors
Abstract

Objective To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March–December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results